Status:
COMPLETED
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Lead Sponsor:
University of Alberta
Conditions:
Covid-19 Infection
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the ...
Detailed Description
PURPOSE: 1. To evaluate the impact of anti-malarial medications (hydroxychloroquine and chloroquine) on the development and severity of COVID-19 infection during the current COVID-19 pandemic in an i...
Eligibility Criteria
Inclusion
- Current active and consented patient of the Rheumatoid Arthritis Pharmacovigilance Program of Northern Alberta with an e-mail or mailing address
Exclusion
- Unable to read English; not consenting to be contacted for future studies
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
773 Patients enrolled
Trial Details
Trial ID
NCT04347798
Start Date
November 1 2020
End Date
June 30 2022
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2G3